BioOutsource is getting prepared for biosimilars boom

November 4, 2014 1:13 PM

BioOutsource Ltd., a company working in biologics contract testing and biosimilar characterisation for the biopharmaceutical industry,  announced a major initiative in new research and development programs to support the next generation of biosimilars.

“We are proud to have established a reputation as one of the top providers in comparability of biosimilars,” commented BioOutsource CEO, Gerry MacKay. “For this, we are deeply appreciative of our existing clients, with whom we have worked closely to develop a range of new assays supporting early stage development.

With global biosimilar sales last year of $1.3 billion expected to explode to $35 billion by 2020, now is the time to leverage our base of knowledge and dramatically expand our R&D efforts to support the next generation of biosimilars. This investment will benefit both new and existing clients and enable them to ride the biosimilars wave with us.”

This major investment in BioOutsource’s  R&D roadmap aims to align the company’s strategy to the next generation of biosimilar molecules including Stelara (ustekinumab, for plaque psoriasis), Yervoy (ipilimumab, for melanoma), Orencia (abatacept, for rheumatoid arthritis), Synagis (palivizumab, for respiratory viral infections) and Actemra (tocilizumab, also for rheumatoid arthritis).

Mr. MacKay added, “We also plan to organize R&D Development Workshops with both current and future clients, to review future biosimilar development and align our R&D activities to support market requirements.  This is all in keeping with our over-riding client-centric focus.”

The new R&D initiative will initially be focused on establishing and validating the primary mechanism of action bioassay and affinity (surface plasmon resonance, SPR), progressing to completion of a new, full biosimilar characterisation package.

Source: BioOutsource

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!